Mentara Therapeutics is an Australia-based neuropsychiatry company developing treatments for neurodegenerative and neuropsychiatric disorders. Its lead asset MTA-304, a highly selective second-generation PDE10A inhibitor acquired from EuMentis Therapeutics, is being developed for levodopa-induced dyskinesia in Parkinson's disease, with a Phase 2 study planned to begin in the first half of 2027. The company is backed by SPRIM Global Investments and led by CEO Frank Stonebanks.
1
Round
1
Industry
5
Tags
Oct 7, 2026
Latest raise
Funding activity · 1 round
Oct 7, 2026
Seed
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
